Phar­ma in­dus­try rep­u­ta­tion scores pos­i­tive bump from in­sulin pric­ing news — Har­ris Poll

In­sulin drug prices and out-of-pock­et costs have been hot top­ics — and a drag on phar­ma in­dus­try rep­u­ta­tion — for years. But now re­cent news from a trio of drug­mak­ers pledg­ing to cap ex­tra costs for con­sumers helped push the en­tire in­dus­try rep­u­ta­tion up­ward, ac­cord­ing to The Har­ris Poll.

In polling meant to gauge the im­pact of the Sil­i­con Val­ley Bank crash and cri­sis, Har­ris found that the phar­ma in­dus­try was on­ly one of two in­dus­tries among 10 ver­ti­cals tracked to record a gain be­tween the time be­fore and af­ter the crash. Pos­i­tive view of phar­ma grew 49%, up 4% from the be­gin­ning to the end of March, the Har­ris sur­vey found. Gov­ern­ment was the oth­er sec­tor gain­ing with a 1% in­crease over the month.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN